Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Technology Officer

400,000 0.6686%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.71%+43.89%+167.15% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -1.45%-1.43%+35.72%+158.32% 25.94B
Weighted average by Cap. +0.17%+0.09%+31.05%+122.81%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock